Kestra Medical Technologies

Kestra Medical names Daniel Finney as its new head of research and development and a member of the executive management team. Finney, previously senior director of new product development at Kestra, succeeds Phillip D. Foshee, Jr., who is retiring. He will advance the ‘‘Cardiac Recovery System’’ platform, including internal R&D, strategic partnerships and AI applications, with a focus on clinical trial and real‑world data. Finney brings more than 20 years of experience in developing Class III medical devices and is to lead the company’s next phase of innovation. » More on de.investing.com

Kestra Medical has appointed Curtis Kopf as senior vice president of customer experience. In the newly created role he will be responsible for the entire patient experience for the wearable cardioverter-defibrillator ASSURE, including order approval, therapy completion and device return. Kopf will lead personnel, process and technological resources and expand use of the ASSURE WCD and the Cardiac Recovery System platform. The appointment is part of Kestra’s investments in commercial capacity and AI‑driven efficiency improvements. » More on de.investing.com

Kestra Medical Technologies will publish the balance sheet for the quarter ended April 30, 2026 on July 14, 2026. Six analysts on average expect a quarterly loss per share of -0.590 USD (prior year: -2.210 USD); seven analysts forecast revenue of an average 26.5 million USD, up about 53.7% from the year-ago quarter. For the most recently completed fiscal year, the consensus is a loss per share of -2.343 USD and revenue of 93.0 million USD (prior year: 59.8 million USD). » More on finanzen.net